2952

GSTT1

-;glutathione S-transferase theta 1;GSTT1;glutathione S-transferase theta 1

GST class-theta-1|glutathione S-transferase theta-1|glutathione transferase T1-1

22q11.23

protein-coding

Count: 2; TAG,Generif

In a study population of 45 patients who were previously enrolled in an imatinib dose escalation trial, genome-wide screening for regions of genetic gains and losses was performed using array comparative genomic hybridization (aCGH). Early molecular response (EMR), defined as >50% reduction in the ratio of BCR-ABL1 to ABL1 within 6 months after dose escalation, was a major endpoint for analysis. After aCGH analysis, copy number change of four genes was investigated in 52 patients as a validation. Copy number gain in 16p11.2 was more frequently observed in patients with EMR than in patients who failed to achieve EMR (P = 0.034). A tendency for increased copy number in 22q11.23 in patients without EMR and for decreased copy number in 17q12 in patients with EMR was observed (P = 0.072 and P = 0.070, respectively). For GSTT1, in 22q11.23, copy number gain was observed in patients without EMR (P = 0.035). GSTT1 copy number gain was related to short time to treatment failure (TTFx) in patients without BCR-ABL1 mutations (P = 0.007). In multivariate analysis, GSTT1 copy number gain was an independent predictive factor for short TTFx (P = 0.020). We conclude that chromosome regions 16p11.2, 22q11.23, and 17q12 are potential locations related to response in imatinib dose escalation therapy for CML. GSTT1 copy number gain is a genetic change affecting outcome in this setting.CI - Copyright (c) 2010 Elsevier Inc. All rights reserved.

Inherited differences in the capacity of xenobiotic metabolizing enzymes might be an important factor in genetic susceptibility to cancer. Null genotypes of glutathione-S-transferases (GSTs) exhibit absence of enzymatic activity and are hypothesized to be at increased risk of developing cancers. The aim of the study was to examine whether null genotypes of GSTM1 and GSTT1 confer susceptibility to chronic myeloid leukemia (CML). We carried a case control study involving 80 consecutive North Indian CML patients (58 males, 22 females; age (mean+/-S.D.) 36.2+/-10.9 years) and 105 healthy individuals (59 males, 46 females; age (mean+/-S.D.) 36.8+/-11.3 years). Multiplex PCR was carried out to determine the frequency of GSTM1 and GSTT1 null genotypes. The relationship between GSTM1, GSTT1 genotypes and risk of CML was assessed by means of odds ratio (OR) with 95% confidence limits calculated by logistic regression. A test for trend (P(trend)) in increasing the risk of CML having more than one putative high-risk allele or genotype was evaluated by means of the chi-square test. There was no difference in the frequencies of the GSTM1 null genotype and the combined GSTM1 and GSTT1 null genotypes between patients and controls in the study. However, statistical significance was found with GSTT1 null genotype frequency in CML patients as compared to controls (16/80 (20%) versus 9/105 (8.5%); OR=2.67, 95% CI: 1.03-7.01). It projects a 2.67-fold increased risk for CML in individuals with GSTT1 null genotype as compared to those possessing both alleles of the gene. Our findings suggest that heritable GST status may influence the risk of developing CML.

It has recently been postulated that the absence of a single tumor suppressor gene (TSG) allele can provide a selective advantage for an emerging tumor cell. We have characterized the precise extension of the deletion on der(9) in 20 chronic myeloid leukemia (CML) cases using FISH analysis with an appropriate set of BAC/PAC probes to attempt a better definition of TSGs encompassed by these genomic deletions. Chromosome 9 deletions on the der(9) were detected in 15 (75%) cases; the TSG PTGES gene was lost in 11 (73%) cases. Chromosome 22 deletions on der(9) were found in 18 (90%) of the analysed cases; two TSGs were found located inside the deleted sequences of chromosome 22: SMARCB1 and GSTT1. These TSGs were found deleted in 16 (89%) cases bearing deletions of chromosome 22. Fourteen (70%) patients were treated with IFN-alpha therapy: 12 did not obtain complete haematologic remission (CHR) and 2 were not evaluable for response. Therefore, the patients did not respond to the IFN-alpha treatment started Glivec obtaining CHR and major cytogenetic response (MCR). The observation that deletions on der(9) are associated with the loss of TSGs suggests their possible involvement in the CML outcome, mediated by a haplo-insufficiency mechanism.